Current studies have elucidated interest on Finerenone as an additional medication that can be used for heart and kidney protective measures in us, PED users.
Unlike spirolactone which interacts with androgen and prolactin receptors, Fineronone acts only on mineral corticoid receptors. This could be a particularly interesting medication for those that run tren.
I’ve implemented at the initial dose of 10mg along side the trifecta of arb, nebivolol and jardiance in hoped that I can mitigate issues with my heart from using gear.
Just opening the topic for discussion.
A brief summary of clinical trials for your review:
Key Finerenone Clinical Trial Findings
Unlike spirolactone which interacts with androgen and prolactin receptors, Fineronone acts only on mineral corticoid receptors. This could be a particularly interesting medication for those that run tren.
I’ve implemented at the initial dose of 10mg along side the trifecta of arb, nebivolol and jardiance in hoped that I can mitigate issues with my heart from using gear.
Just opening the topic for discussion.
A brief summary of clinical trials for your review:
Key Finerenone Clinical Trial Findings
- FINE-ONE Trial (Type 1 Diabetes & CKD): Found in 2025 that finerenone significantly reduced the urine albumin-to-creatinine ratio (UACR) by 25% over six months compared to placebo, showing safety consistent with T2D trials.
- FIND-CKD Trial (Non-Diabetic CKD): Reported in March 2026 that finerenone met its primary endpoint, significantly delaying kidney disease progression compared to placebo in patients with non-diabetic chronic kidney disease.
- FINEARTS-HF Trial (Heart Failure): Indicated that finerenone reduced the rate of composite outcomes (worsening heart failure events and cardiovascular death) in patients with mildly reduced or preserved ejection fraction.
- FIDELIO-DKD & FIGARO-DKD (T2D & CKD): These landmark Phase 3 trials showed a reduced risk of chronic kidney disease progression and cardiovascular events (e.g., hospitalization for heart failure).
- Safety Profile: Across studies, the most common adverse event of special interest is hyperkalemia (high potassium), though treatment discontinuation rates for this remain relatively low (1.7% in FINE-ONE).















































































